{"id":46840,"date":"2022-08-02T17:01:42","date_gmt":"2022-08-02T15:01:42","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/otsuka-pharmaceutical-and-lundbeck-to-present-phase-3-data-for-brexpiprazole-in-patients-with-alzheimers-dementia-at-aaic-2022\/"},"modified":"2022-08-02T17:01:42","modified_gmt":"2022-08-02T15:01:42","slug":"otsuka-pharmaceutical-and-lundbeck-to-present-phase-3-data-for-brexpiprazole-in-patients-with-alzheimers-dementia-at-aaic-2022","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/otsuka-pharmaceutical-and-lundbeck-to-present-phase-3-data-for-brexpiprazole-in-patients-with-alzheimers-dementia-at-aaic-2022\/","title":{"rendered":"Otsuka Pharmaceutical and Lundbeck to Present Phase 3 Data for Brexpiprazole in Patients with Alzheimer\u2019s Dementia at AAIC 2022"},"content":{"rendered":"
\n

\nResearchers to highlight positive results from a phase 3 clinical study for treatment of agitation in patients with Alzheimer\u2019s dementia<\/i>\n<\/p>\n

PRINCETON, N.J. & DEERFIELD, Ill.–(BUSINESS WIRE)–Otsuka Pharmaceutical Development & Commercialization, Inc., and H. Lundbeck A\/S (Lundbeck) today announce that new Phase 3 data for brexpiprazole will be presented at the 2022 Alzheimer\u2019s Association International Conference (AAIC)<\/a>, which is being held virtually and in San Diego from July 31 through August 4. The oral presentation will be featured in the Neuropsychiatry and Behavioral Neurology: Agitation and Psychosis session on Thursday, August 4 from 9:45am to 11:00am PT.\n<\/p>\n

\n\u201cWe are excited to be presenting data that further advances a possible option for a significant unmet need among this patient community,\u201d said Robert McQuade, PhD, executive vice president, chief strategic officer and interim chief medical officer, Otsuka Pharmaceutical Development & Commercialization, Inc.\n<\/p>\n

\nDr. Johan Luthman, executive vice president and head of Research & Development at Lundbeck commented, \u201cAgitation is a very prevalent clinical manifestation in Alzheimer\u2019s dementia and can have a significant impact on the quality of life among patients affected by the disease and their caregivers.\u201d\n<\/p>\n

\nCurrently there are no FDA-approved pharmacological treatments for agitation in Alzheimer\u2019s dementia.\n<\/p>\n

\nThe 2022 AAIC agenda can be viewed here<\/a>.\n<\/p>\n

\nAbout H. Lundbeck A\/S<\/b>\n<\/p>\n

\nLundbeck is a global pharmaceutical company specialized in brain diseases. For more than 70 years, we have been at the forefront of neuroscience research. We are tirelessly dedicated to restoring brain health, so every person can be their best. We are committed to fighting stigma and discrimination against people living with brain diseases and advocating for broader social acceptance of people with brain health conditions. Our research programs tackle some of the most complex challenges in neuroscience, and our pipeline is focused on bringing forward transformative treatments for brain diseases for which there are few, if any therapeutic options.\n<\/p>\n

\nFor additional information, we encourage you to visit our corporate site www.lundbeck.com<\/a> and connect with us on Instagram (h_lundbeck), Twitter at @Lundbeck and via LinkedIn.\n<\/p>\n

\nAbout Otsuka<\/span><\/b>\n<\/p>\n

\nOtsuka Pharmaceutical Co., Ltd. is a global healthcare company with the corporate philosophy: \u201cOtsuka\u2013people creating new products for better health worldwide.\u201d Otsuka researches, develops, manufactures, and markets innovative products, with a focus on pharmaceutical products to meet unmet medical needs and nutraceutical products for the maintenance of everyday health.\n<\/p>\n

\nIn pharmaceuticals, Otsuka is a leader in the challenging areas of mental, renal, and cardiovascular health and has additional research programs in oncology and on several under-addressed diseases including tuberculosis, a significant global public health issue. These commitments illustrate how Otsuka is a \u201cbig venture\u201d company at heart, applying a youthful spirit of creativity in everything it does.\n<\/p>\n

\nOtsuka established a presence in the U.S. in 1973. Today, through holdings company, Otsuka America, Inc. (OAI), its affiliates Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC) and Otsuka America Pharmaceutical, Inc. (OAPI), employ 1,700 U.S. employees. Both develop and commercialize medicines in the areas of mental health, nephrology, and cardiology, using cutting-edge technology to address unmet healthcare needs.\n<\/p>\n

\nOPDC and OAPI are indirect subsidiaries of Otsuka Pharmaceutical Company, Ltd., which is a subsidiary of Otsuka Holdings Co., Ltd. headquartered in Tokyo, Japan. The Otsuka group of companies employed 47,000 people worldwide and had consolidated sales of approximately USD 13.6 billion in 2021.\n<\/p>\n

\nAll Otsuka stories start by taking the road less traveled. Learn more about Otsuka in the U.S. at www.otsuka-us.com<\/a> and connect with us on LinkedIn<\/a> and Twitter at @OtsukaUS<\/a>. Otsuka Pharmaceutical Co., Ltd.\u2019s global website is accessible at www.otsuka.co.jp\/en\/<\/a>.\n<\/p>\n

Contacts<\/b> <\/p>\n

\nMEDIA<\/b>
Otsuka in US<\/b>
Robert Murphy
\n
Corporate Communications
\n
Otsuka America Pharmaceutical, Inc.
\n
robert.murphy@otsuka-us.com<\/a>
Phone: +1 609 249 7262\n<\/p>\n

\nOtsuka in Japan<\/b>
Jeffrey Gilbert (Outside the US)
\n
Leader, Pharmaceutical PR
\n
Otsuka Pharmaceutical, Co., Ltd.
\n
gilbert.jeffrey@otsuka.co.jp<\/a>
Phone: +81 3 6361 7379\n<\/p>\n

\nLundbeck in US<\/b>
Dyana Lescohier
\n
Corporate Communications
\n
DYLE@lundbeck.com<\/a>
Phone: +1 847 894 3586\n<\/p>\n

\nLundbeck in Denmark<\/b>
Thomas Mikkel Mortensen (Outside the US)
\n
Media Relations Lead,
\n
Corp. Communication
\n
THMR@lundbeck.com<\/a>
Phone: +45 30 83 30 24\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

Researchers to highlight positive results from a phase 3 clinical study for treatment of agitation in patients with Alzheimer\u2019s dementia PRINCETON, N.J. & DEERFIELD, Ill.–(BUSINESS WIRE)–Otsuka Pharmaceutical Development & Commercialization, Inc., and H. Lundbeck A\/S (Lundbeck) today announce that new Phase 3 data for brexpiprazole will be presented at the 2022 Alzheimer\u2019s Association International Conference … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-46840","6":"format-standard","7":"category-industry"},"yoast_head":"\nOtsuka Pharmaceutical and Lundbeck to Present Phase 3 Data for Brexpiprazole in Patients with Alzheimer\u2019s Dementia at AAIC 2022 - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/otsuka-pharmaceutical-and-lundbeck-to-present-phase-3-data-for-brexpiprazole-in-patients-with-alzheimers-dementia-at-aaic-2022\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Otsuka Pharmaceutical and Lundbeck to Present Phase 3 Data for Brexpiprazole in Patients with Alzheimer\u2019s Dementia at AAIC 2022 - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"Researchers to highlight positive results from a phase 3 clinical study for treatment of agitation in patients with Alzheimer\u2019s dementia PRINCETON, N.J. & DEERFIELD, Ill.–(BUSINESS WIRE)–Otsuka Pharmaceutical Development & Commercialization, Inc., and H. Lundbeck A\/S (Lundbeck) today announce that new Phase 3 data for brexpiprazole will be presented at the 2022 Alzheimer\u2019s Association International Conference ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/otsuka-pharmaceutical-and-lundbeck-to-present-phase-3-data-for-brexpiprazole-in-patients-with-alzheimers-dementia-at-aaic-2022\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-08-02T15:01:42+00:00\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/otsuka-pharmaceutical-and-lundbeck-to-present-phase-3-data-for-brexpiprazole-in-patients-with-alzheimers-dementia-at-aaic-2022\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/otsuka-pharmaceutical-and-lundbeck-to-present-phase-3-data-for-brexpiprazole-in-patients-with-alzheimers-dementia-at-aaic-2022\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Otsuka Pharmaceutical and Lundbeck to Present Phase 3 Data for Brexpiprazole in Patients with Alzheimer\u2019s Dementia at AAIC 2022\",\"datePublished\":\"2022-08-02T15:01:42+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/otsuka-pharmaceutical-and-lundbeck-to-present-phase-3-data-for-brexpiprazole-in-patients-with-alzheimers-dementia-at-aaic-2022\\\/\"},\"wordCount\":679,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/otsuka-pharmaceutical-and-lundbeck-to-present-phase-3-data-for-brexpiprazole-in-patients-with-alzheimers-dementia-at-aaic-2022\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/otsuka-pharmaceutical-and-lundbeck-to-present-phase-3-data-for-brexpiprazole-in-patients-with-alzheimers-dementia-at-aaic-2022\\\/\",\"name\":\"Otsuka Pharmaceutical and Lundbeck to Present Phase 3 Data for Brexpiprazole in Patients with Alzheimer\u2019s Dementia at AAIC 2022 - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"datePublished\":\"2022-08-02T15:01:42+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/otsuka-pharmaceutical-and-lundbeck-to-present-phase-3-data-for-brexpiprazole-in-patients-with-alzheimers-dementia-at-aaic-2022\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/otsuka-pharmaceutical-and-lundbeck-to-present-phase-3-data-for-brexpiprazole-in-patients-with-alzheimers-dementia-at-aaic-2022\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/otsuka-pharmaceutical-and-lundbeck-to-present-phase-3-data-for-brexpiprazole-in-patients-with-alzheimers-dementia-at-aaic-2022\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Otsuka Pharmaceutical and Lundbeck to Present Phase 3 Data for Brexpiprazole in Patients with Alzheimer\u2019s Dementia at AAIC 2022\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Otsuka Pharmaceutical and Lundbeck to Present Phase 3 Data for Brexpiprazole in Patients with Alzheimer\u2019s Dementia at AAIC 2022 - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/otsuka-pharmaceutical-and-lundbeck-to-present-phase-3-data-for-brexpiprazole-in-patients-with-alzheimers-dementia-at-aaic-2022\/","og_locale":"en_US","og_type":"article","og_title":"Otsuka Pharmaceutical and Lundbeck to Present Phase 3 Data for Brexpiprazole in Patients with Alzheimer\u2019s Dementia at AAIC 2022 - Pharma Trend","og_description":"Researchers to highlight positive results from a phase 3 clinical study for treatment of agitation in patients with Alzheimer\u2019s dementia PRINCETON, N.J. & DEERFIELD, Ill.–(BUSINESS WIRE)–Otsuka Pharmaceutical Development & Commercialization, Inc., and H. Lundbeck A\/S (Lundbeck) today announce that new Phase 3 data for brexpiprazole will be presented at the 2022 Alzheimer\u2019s Association International Conference ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/otsuka-pharmaceutical-and-lundbeck-to-present-phase-3-data-for-brexpiprazole-in-patients-with-alzheimers-dementia-at-aaic-2022\/","og_site_name":"Pharma Trend","article_published_time":"2022-08-02T15:01:42+00:00","author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/otsuka-pharmaceutical-and-lundbeck-to-present-phase-3-data-for-brexpiprazole-in-patients-with-alzheimers-dementia-at-aaic-2022\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/otsuka-pharmaceutical-and-lundbeck-to-present-phase-3-data-for-brexpiprazole-in-patients-with-alzheimers-dementia-at-aaic-2022\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Otsuka Pharmaceutical and Lundbeck to Present Phase 3 Data for Brexpiprazole in Patients with Alzheimer\u2019s Dementia at AAIC 2022","datePublished":"2022-08-02T15:01:42+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/otsuka-pharmaceutical-and-lundbeck-to-present-phase-3-data-for-brexpiprazole-in-patients-with-alzheimers-dementia-at-aaic-2022\/"},"wordCount":679,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/otsuka-pharmaceutical-and-lundbeck-to-present-phase-3-data-for-brexpiprazole-in-patients-with-alzheimers-dementia-at-aaic-2022\/","url":"https:\/\/pharma-trend.com\/en\/otsuka-pharmaceutical-and-lundbeck-to-present-phase-3-data-for-brexpiprazole-in-patients-with-alzheimers-dementia-at-aaic-2022\/","name":"Otsuka Pharmaceutical and Lundbeck to Present Phase 3 Data for Brexpiprazole in Patients with Alzheimer\u2019s Dementia at AAIC 2022 - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"datePublished":"2022-08-02T15:01:42+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/otsuka-pharmaceutical-and-lundbeck-to-present-phase-3-data-for-brexpiprazole-in-patients-with-alzheimers-dementia-at-aaic-2022\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/otsuka-pharmaceutical-and-lundbeck-to-present-phase-3-data-for-brexpiprazole-in-patients-with-alzheimers-dementia-at-aaic-2022\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/otsuka-pharmaceutical-and-lundbeck-to-present-phase-3-data-for-brexpiprazole-in-patients-with-alzheimers-dementia-at-aaic-2022\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Otsuka Pharmaceutical and Lundbeck to Present Phase 3 Data for Brexpiprazole in Patients with Alzheimer\u2019s Dementia at AAIC 2022"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/46840","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=46840"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/46840\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=46840"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=46840"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=46840"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}